The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

Published Date: 08 Apr 2024

In three trials, the response rate was about half the patients, and it lasted for up to 19 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How AI will transform mental health support for patients with breast cancer

2.

US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry

3.

Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat

4.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

5.

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot